Pharmacia, Merck Explain FDA Cmte. Review Of COX-2 Safety To Investors

Pharmacia expects both its COX-2 inhibitor Celebrex and Merck's competing Vioxx to receive comparable gastrointestinal safety labeling following a Feb. 7-8 FDA advisory committee meeting.